Reviewer’s report

Title: Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen

Version: 2 Date: 29 June 2015

Reviewer: Gabriela Kornek

Reviewer’s report:

This is an excellent written manuscript of a well-designed phase II/ randomized phase III trial. The rationale for this trial is of greater interest for physicians and investigator in the US and of marginal interest in Europe. There is only one (but “major compulsory”) question/comment: The number of included patients was lower than the planned number of 200 because (?) the supply of one study drug expired during the study period. This fact should be mentioned in the discussion.

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: Yes, but I do not feel adequately qualified to assess the statistics.

Declaration of competing interests:

I declare that I have no competing interests